

Press Release

Würselen / Munich, 11 May 2010



PINOVA Capital takes a participation in Hemoteq AG

PINOVA Capital, a Munich-based independent private equity firm, today announced an investment into Hemoteq AG in Würselen. As part of the transaction, CFO Thomas Löwen also acquires a stake in the company.

Hemoteq is a leading specialist in the market for biocompatible and drug eluting surfaces. The company develops ultrathin functional coatings and surface modification solutions for medical devices, supports its customers with comprehensive services to obtain regulatory approval and provides high level clean room capacities for volume production. The application focus is on cardiology, ophthalmology, orthopedics and dentistry. Hemoteq has a large customer base including leading European, North American and Asian medical device manufacturers.

PINOVA acquired the stake of an existing shareholder in April 2010 and will support further growth of the company. Marko Maschek, partner at PINOVA, will join the advisory board.

"Hemoteq operates in a market which among others is strongly driven by demographic change. With its strong growth and patented technology, the company clearly is a candidate for an IPO within the coming years" comments Marko Maschek.

"We are pleased to have won PINOVA as an investor who supports our further international growth. PINOVA's partners' experience in international expansion and their network will play an important role in this" explains Michael Hoffmann, CEO of Hemoteq AG.

About PINOVA Capital

PINOVA Capital is an independent Private Equity firm focusing on high growth Engineering and Services companies in German speaking Europe.

The fund invests equity between € 3 million and € 15 million taking minority and majority positions in companies within a revenue bracket of € 5 million to € 100 million.

PINOVA Capital was founded by four partners, Katrin Brökelmann, Marko Maschek, Martin Olbort and Joern Pelzer, with longstanding experience in Private Equity, an entrepreneurial Mittelstand background and an international network.



PINOVA Fund I is supported by the European Union through the "Competitiveness and Innovation Framework Programme" ("CIP").

About Hemoteq AG

Hemoteq develops ultrathin functional coatings and surface solutions for medical devices, supports its customers with comprehensive services to obtain regulatory approval and provides high level clean room capacities for volume production. The company puts a strong emphasis on individual customer needs and customer specific solutions. Hemoteq has a unique and patented technology portfolio as well as an exceptional track record in high-quality innovative surface coating technologies

Hemoteq was founded in 1999 by Dr. Michael Hoffmann and Roland Horres out of RWTH Aachen, a world-renowned university which enjoys promotion under the German Federal Government's "Initiative for Excellence". The company is located in Würselen, near Aachen in the centre of the "Euregio", which stands out for its manifold and innovative research activity as well as its international environment.

Contact PINOVA Capital

Katrin Brökelmann
Partner

katrin.broekelmann@pinovacapital.com

PINOVA Capital GmbH
Rindermarkt 7,
80331 Munich, Germany

T: +49 (0) 89. 189 42 54 – 40

F: +49 (0) 89. 189 42 54 – 69

www.pinovacapital.com

Contact Hemoteq:

Dr. Michael Hoffmann
Vorstandsvorsitzender

Hemoteq AG
Adenauerstrasse 15,
52146 Würselen, Germany

T: +49(0) 2405. 455 0 - 100

F: +49 (0) 2405. 455 0 - 155

www.hemoteq.de